HC Wainwright Has Positive Outlook for CGTX FY2026 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Research analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of Cognition Therapeutics in a research report issued to clients and investors on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.18) for the year, up from their prior estimate of ($0.20). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q4 2026 earnings at ($0.04) EPS, Q1 2027 earnings at ($0.04) EPS, Q2 2027 earnings at ($0.04) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.18) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03.

Other equities research analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Cognition Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Monday, September 21st. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $3.33.

Cognition Therapeutics Trading Down 3.0%

Shares of CGTX opened at $0.67 on Wednesday. Cognition Therapeutics has a one year low of $0.55 and a one year high of $1.81. The company has a 50-day moving average of $0.87 and a two-hundred day moving average of $1.04.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CGTX. Bryn Mawr Trust Advisors LLC purchased a new position in shares of Cognition Therapeutics during the second quarter valued at $33,000. StoneX Group Inc. purchased a new stake in Cognition Therapeutics in the 3rd quarter worth about $30,000. Lido Advisors LLC purchased a new stake in Cognition Therapeutics in the 3rd quarter worth about $44,000. Corient Private Wealth LP purchased a new stake in Cognition Therapeutics in the 2nd quarter worth about $93,000. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new stake in Cognition Therapeutics during the 2nd quarter worth about $165,000. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Key Headlines Impacting Cognition Therapeutics

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its 2026 and 2027 earnings forecasts, narrowing its projected annual loss to $0.18 per share from $0.20 and $0.19, respectively. It also improved several quarterly estimates to a loss of $0.04 per share from $0.05 and maintained its Buy rating.
• Positive Sentiment: Cognition Therapeutics was upgraded to Zacks Rank #2 (Buy), reflecting improving earnings expectations and potentially bolstering near-term sentiment. Article: What Makes Cognition Therapeutics (CGTX) a New Buy Stock
• Neutral Sentiment: CEO Lisa Ricciardi plans to attend the Jefferies Global Healthcare Conference on November 16–19 and discuss the company’s recent FDA meeting on endpoints for a planned Phase 3 zervimesine study in dementia with Lewy bodies. No new FDA decision or trial outcome was announced. Article: Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
• Neutral Sentiment: A short-interest report described a large increase but listed total short interest as zero shares, making the figures inconsistent and difficult to interpret.
• Negative Sentiment: At the provided $0.67 reference price, CGTX remains below its 50-day ($0.87) and 200-day ($1.04) moving averages, indicating a weaker recent technical trend despite the positive analyst revisions.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as the sigma-2 receptor complex or PGRMC1, a target believed to play a role in the cellular mechanisms associated with synaptic dysfunction and neurodegeneration. Cognition Therapeutics’ lead product candidate is CT1812, an orally administered small-molecule therapy designed to modulate the sigma-2 receptor complex.